Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
328 stopped studies mapped to Myelodysplastic Syndrome and descendants · 88% state a reason
Over the 328 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03059615 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects… | Phase 2 | withdrawn | Feb 23, 2017 | Immune System Key Ltd | No recruitment since initiation | Enrollment / accrual |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic… | Phase 1 / Phase 2 | withdrawn | Jul 10, 2019 | Vanderbilt-Ingram Cancer Center | Loss of funding | Funding |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | Phase 2 | terminated | Oct 24, 2018 | NYU Langone Health | Safety concerns | Safety / toxicity |
| NCT02923986 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2016 | Bio-Path Holdings, Inc. | No enrollment | Enrollment / accrual |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | Phase 2 | terminated | Mar 17, 2006 | Masonic Cancer Center, University of Minnesota | IRB Study Closure | Other (stated, no rule matched) |
| NCT02370888 | Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia…(UF-BMT-MRD-101) | Phase 1 | terminated | Feb 25, 2015 | University of Florida | Slow accrual | Enrollment / accrual |
| NCT02226497 | Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic… | N/A | terminated | Aug 27, 2014 | Fred Hutchinson Cancer Center | Insufficient staff | Other (stated, no rule matched) |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT00973804 | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched… | Phase 1 | terminated | Sep 9, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells… | Phase 1 | terminated | Sep 4, 2014 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
| NCT00085449 | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate… | Phase 1 / Phase 2 | withdrawn | Jun 11, 2004 | Alliance for Clinical Trials in Oncology | Funding cut, no patients enrolled | Enrollment / accrual |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem… | — | terminated | Apr 3, 2008 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | Phase 1 | withdrawn | Aug 2, 2018 | Celyad Oncology SA | Sponsor decision | Sponsor / business decision |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | Phase 1 / Phase 2 | terminated | Dec 11, 2012 | Washington University School of Medicine | Enrolling 8 more patients would be statistically unlikely that the primary endpoint would be… | Enrollment / accrual |
| NCT02053545 | Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo… | Phase 1 / Phase 2 | withdrawn | Feb 3, 2014 | Ann & Robert H Lurie Children's Hospital of Chicago | Study closed with no enrollment. | Enrollment / accrual |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | Phase 2 | terminated | Sep 14, 2005 | Masonic Cancer Center, University of Minnesota | Accrual Goal Met | Enrollment / accrual |
| NCT02360111 | GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal… | N/A | terminated | Feb 10, 2015 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT03735446 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a… | Phase 1 | terminated | Nov 8, 2018 | Dana-Farber Cancer Institute | Sponsor Decision | Sponsor / business decision |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk… | Phase 1 | terminated | Apr 25, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study drug supply expired and could not be renewed. | Drug supply |
| NCT02627573 | Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | Phase 2 | terminated | Dec 11, 2015 | St. Petersburg State Pavlov Medical University | Poor recruitment | Enrollment / accrual |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing…(N1) | — | terminated | Sep 14, 2016 | CureOne | Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. | Other (stated, no rule matched) |
| NCT01116232 | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease… | Phase 2 | terminated | May 4, 2010 | Barbara Ann Karmanos Cancer Institute | Lack of funding. | Funding |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or… | Phase 1 / Phase 2 | terminated | Apr 16, 2015 | Spirita Oncology, LLC | Insufficient efficacy in Phase 1 dose-escalation portion of study | Efficacy / futility |
| NCT01957644 | Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients… | Phase 1 | terminated | Oct 8, 2013 | Boehringer Ingelheim | not stated | Not stated |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk… | Phase 1 / Phase 2 | terminated | Apr 9, 2008 | Viron Therapeutics Inc | not stated | Not stated |
| NCT00074490 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and… | Phase 2 | terminated | Dec 15, 2003 | National Cancer Institute (NCI) | Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2 | Enrollment / accrual |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | Phase 1 | terminated | Feb 17, 2016 | Plexxikon | Business Decision | Sponsor / business decision |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT02676323 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid… | Phase 1 | terminated | Feb 8, 2016 | St. Jude Children's Research Hospital | Slow accrual | Enrollment / accrual |
| NCT03365661 | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | Phase 2 | withdrawn | Dec 7, 2017 | Masonic Cancer Center, University of Minnesota | Sponsor halted study. | Other (stated, no rule matched) |
| NCT00212407 | New York Blood Center National Cord Blood Program | Early Phase 1 | terminated | Sep 21, 2005 | New York Blood Center | Study NCT01656603 supersedes this study; FDA IND 6637 | Other (stated, no rule matched) |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | Phase 1 / Phase 2 | terminated | Aug 15, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02992860 | Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED…(SAMBA) | Phase 2 | terminated | Dec 14, 2016 | GWT-TUD GmbH | Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with… | Enrollment / accrual |
| NCT02641002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk… | Phase 1 | terminated | Dec 29, 2015 | Celgene | Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a… | Other (stated, no rule matched) |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00398047 | Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating… | Phase 2 | terminated | Nov 10, 2006 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00939159 | Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome… | Phase 2 | terminated | Jul 14, 2009 | M.D. Anderson Cancer Center | Low Accrual | Enrollment / accrual |
| NCT00356928 | Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies | Phase 1 | terminated | Jul 27, 2006 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Poor accrual | Enrollment / accrual |
| NCT00104806 | Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With… | Phase 2 | terminated | Mar 4, 2005 | Wake Forest University Health Sciences | sponsor discontinues support | Other (stated, no rule matched) |
| NCT01598025 | Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an… | N/A | terminated | May 15, 2012 | Memorial Sloan Kettering Cancer Center | Closed due to poor accrual | Enrollment / accrual |
| NCT03086252 | Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study | N/A | withdrawn | Mar 22, 2017 | Emory University | Slow accrual | Enrollment / accrual |
| NCT01795924 | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia…(AML/MDS) | Phase 1 / Phase 2 | terminated | Feb 21, 2013 | Biosuccess Biotech Co., Ltd. | Difficulty of patient enrollment | Enrollment / accrual |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood… | Phase 2 | terminated | Dec 10, 2012 | Weill Medical College of Cornell University | Slow accrual | Enrollment / accrual |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | Phase 1 / Phase 2 | terminated | Jan 15, 2010 | Everett Meyer | Safety | Safety / toxicity |
| NCT00118196 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or… | Phase 2 | terminated | Jul 11, 2005 | Medical University of South Carolina | Due to limited resources available to conduct study | Other (stated, no rule matched) |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | Phase 1 / Phase 2 | terminated | Feb 29, 2008 | Milton S. Hershey Medical Center | Investigator decision | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 31, 2020source: clinicaltrials